Usage and dosage of lung cancer drug serpatinib and introduction to medication for special groups

Introduction: Selpercatinib is a targeted therapy drug used to treat certain types of thyroid cancer and non-small cell lung cancer (NSCLC). Depending on the disease and condition, the patient's usage and dosage may be different. This article mainly talks about the usage and dosage of serpatinib, medication for special groups, etc.

Usage and Dosage

1. Adult patients with non-small cell lung cancer (NSCLC) and thyroid cancer:

Weight less than 50kg: Take 120 mg orally daily (60 mg twice daily, approximately every 12 hours) until disease progression or unacceptable toxicity.

Weight 50 kg or greater: 160 mg orally daily (80 mg twice daily, approximately every 12 hours) until disease progression or unacceptable toxicity.

2. Pediatric patients with thyroid cancer (12 years old and above):

Weight less than 50kg: Take 120mg orally daily (60mg twice daily, approximately every 12 hours) until disease progression or unacceptable toxicity occurs.

Weight 50 kg or greater: 160 mg orally daily (80 mg twice daily, approximately every 12 hours) until disease progression or unacceptable toxicity.

3. Adult patients with solid tumors:

Weight less than 50kg: Take 120 mg orally daily (twice a day, 60 mg each time, approximately every 12 hours) until disease progression or unacceptable toxicity occurs.

Weight 50 kg or greater: 160 mg orally daily (80 mg twice daily, approximately every 12 hours) until disease progression or unacceptable toxicity.

Patients should swallow the capsule whole and do not crush or chew it. If a dose is missed and it is more than 6 hours before the next dose, the missed dose should be taken.

Usage for special groups

1. Patients with hepatic insufficiency: Since serpatinib is mainly metabolized by the liver in the body, patients with hepatic insufficiency may need to adjust the dose. Patients with severe hepatic impairment should have their RETEVMO dose reduced accordingly.

2. Breastfeeding women: It is unclear whether serpatinib is passed through breast milk. Therefore, breastfeeding women should consult their doctor whether they can continue breastfeeding or choose to stop breastfeeding.

3. Pregnant women: Women who are pregnant or planning to become pregnant should discuss the risks and benefits with their doctor before using serpatinib. Women should use effective contraceptive methods during treatment to avoid possible adverse effects on the fetus.

4. Risk of impaired wound healing: Do not use serpatinib at least 7 days before elective surgery. Do not give this medication for at least 2 weeks after major surgery and until the wound has healed. The safety of continued use of serpatinib after resolution of wound healing complications has not been established.

The use of serpatinib in special populations needs to be adjusted according to the specific conditions of the patient. Before taking medication, patients should explain their health conditions and medication history to the doctor in detail so that the doctor can develop an appropriate medication plan. At the same time, patients should strictly follow the doctor's instructions to take medication and receive regular examinations from the doctor to ensure the safety and effectiveness of the treatment.